MILAN--(BUSINESS WIRE)--Sorin Group (Reuters Code: SORN.MI) (MIL:SRN), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today a minority investment in Enopace Biomedical, an early-stage company focused on the development of a neuromodulation system to treat patients with congestive heart failure.
